April 17th, 2020
COVID-19 Physician Town Hall
2
ReflectionRobyn Parker, VP Strategy & Network Development
3
You
are
HOPE
4
Opening RemarksDon Franke, SVP, Population Health and CEO, AMITA Health Care Networks
5
Meeting Agenda
ReflectionRobyn Parker
VP Strategy & Network Development
OpeningDon Franke
SVP, Population Health and CEO, AMITA Health Care Networks
AMITA COVID-19 Command CenterDr. Stuart Marcus
EVP, Chief Clinical Officer
Testing GuidanceDr. Mark Collins
CIN Medical Director
Infectious Disease Clinical ApproachDr. Ram Ramani
Infectious Disease MD, Metro Infectious Disease Consultants
Cardiology Response
Dr. Daniel Sauri
Director of Noninvasive Cardiology and Cardiac Imaging, AMITA Heart and
Vascular Medical Group, Cardiovascular Associates
Medications and TreatmentSun Lee-Such
Vice President Pharmacy Services
Respiratory ClinicsDr. Reinhold Llerena
President, AMITA Medical Group
Closing RemarksDr. Joseph Lagattuta
CIN Board Chair
6
Updated Hours:
AMITA Physician Hotline Phone Number
224.273.3900 from 8am to 5pm weekdays for the foreseeable future
AMITA Physician Hotline Email
7
AMITA Health COVID-19 Resource PageAMITA Health COVID-19 Resources Playbooks can be found here: AMITAhealth.org/covid-19-AMITA
8
Playbook and Supplemental Documentation UpdatesA summary of newly available or updated resources on the AMITA COVID-19 site (AMITAhealth.org/covid-19-
AMITA) can be found in the “For Our Medical Staff” section of the nightly Leader and Physician Update.
9
AMITA COVID-19 Command Center Dr. Stuart Marcus, EVP, Chief Clinical Officer
10
Joe Impicciche Named to President Trump’s Economic Revival Task Force
11
AMITA Health COVID-19 Daily DashboardUpdated: April 16th
AMITAhealth.org/covid-19-AMITA
12
AMITA Health COVID-19 Daily DashboardUpdated: April 16th
AMITAhealth.org/covid-19-AMITA
13
AMITA Health COVID-19 Daily DashboardUpdated: April 16th
14
AMITA Health COVID-19 Daily DashboardUpdated: April 16th
15
Testing UpdateDr. Mark Collins, CIN Medical Director
16
CDC Guidelines for Testing Prioritization
Document can be found under Testing Guidance section at AMITAhealth.org/covid-19-AMITA
17
COVID-19 Commercial Testing Algorithm in Ambulatory Setting
Document can be found under Testing Guidance section at AMITAhealth.org/covid-19-AMITA
18
COVID-19 Commercial Testing Algorithm in Ambulatory Setting - continued
Table 2 – COVID-19 Evaluation and Testing (if indicated)Independent Physicians fax referral form and requested documents. Site will contact patient to schedule appointment
Location Address Referral required Pre-Registration
RequiredTimes Special Instructions
AMITA Health
Mount Prospect
1754 W Golf
Road. Mt
Prospect, Il
60056
Yes
Fax Referral form to
224-265-9041
or
(call 224-265-9000; option 2 if
unable to fax)
Yes
Patient will be
contacted once
referral is received
8am-5pmPatient stays in car and calls front desk upon arrival
224-265-9000 (press 2 for immediate care)
AMITA Health
Lincolnwood
7380 N Lincoln
Lincolnwood, IL
60712
Yes
Fax Referral Form to
847-568-7440
or
(call 847-568-7400 if unable to fax)
Yes
Patient will be
contacted once
referral is received
8am-5pmPatient stays in car and calls front desk upon arrival
847-568-7400
AMITA Health
Chicago-Archer
6084 S. Archer
Floor 1
Chicago, IL
60638
Yes
Fax Referral Form to
224-273-6099
or
(call 224-273-6000 if unable to fax)
Yes
Patient will be
contacted once
referral is received
8am-5pmPatient walks to the rear entrance and calls front
desk upon arrival 224-273-6004
Table 1 – COVID-19 Testing ONLYRegistrar will contact patient to schedule appointment and coordinate drive through testing. Tell patient to be prepared to answer the call.
Location AddressOrder
required Pre-Registration Required Times Special Instructions
AMITA Health
St Alexius
Medical Center
1555 Barrington
Rd
Hoffman Estates,
60169
Yes
Fax order to
847-590-2634
Yes
Email copy of order form to AMITA-MB-
Central.Sched.COVID-
To initiate the scheduling process
10am-2pm
• Patients must obtain order from PCP
• Associates contact local Associate Health
• Medical Staff call Medical Staff Hotline at 224-273-
3900
AMITA Health
St Francis
Hospital
355 Ridge Ave
Evanston,
60202
Yes
Fax order to
312-770-2530
Yes
Email copy of order form to AMITA-MB-
Central.Sched.COVID-
To initiate the scheduling process
1pm-5pm
• Patients must obtain order from PCP
• Associates contact local Associate Health
• Medical Staff call Medical Staff Hotline at 224-273-
3900
AMITA Health
St Joseph
Medical Center
– Joliet
333 N Madison
St
Joliet,
60435
Yes
Fax order to
844-569-4066
NO
Receipt of outpatient testing order form will
initiate scheduling
9am-3pm
Document can be found under Testing Guidance section at AMITAhealth.org/covid-19-AMITA
19
Regional Drive-Through Testing Locations
• Northwest: AMITA Health St.
Alexius Medical Center Hoffman
Estates
• Chicago Metro: AMITA Health
Saint Francis Hospital Evanston
• South: AMITA Health Saint Joseph
Medical Center Joliet
AMITA Health is offering drive-through COVID-19 testing at three regional sites for physicians, support staff,
associates, and patients who have been screened and deemed appropriate for testing. Orders are required.
1
2
3
1
2
3
20
Tests Available – Not Yet FDA Approved
While we are continually assessing all available tests, the state of testing is in flux. As of now there is no FDA
approved test, so any test is only as good as the physician’s ability to interpret and utilize it clinically. That said,
below is an overview of currently available Antibody, PCR Rapid, and PCR tests.
Abbott is developing an additional antibody test to determine immunity status to
COVID-19. The test is anticipated to be released at the end of April or early May 2020.
Test Name Test Type Methodology Run TimeTurnaround Time
Depending on local
process
Sensitivity@ AMITA /
Alverno
IgM/IgG Antibody
Blood Test1 Antibody Blood test 15 minutes 60 minutesPending further
testing
Abbott ID NOW
Test1,2
PCR
RAPID
Nasopharyngeal
Swab15 minutes 60 minutes
>1,000 cp/ml*Yes
Cepheid Xpert
Xpress
SARS-CoV-2
PCR
RAPID
Nasopharyngeal
Swab45 minutes 60 minutes 250 cp/ml
DiaSorin PCR
Nasopharyngeal
Swab 90 minutes 3-6 hours 500 cp/ml Yes
AB7500 PCR
Nasopharyngeal
Swab Up to 8 hours 12-24 hours 80 cp/ml
Abbott M2000 PCRNasopharyngeal
SwabUp to 8 hours 12-24 hours 100 cp/ml Yes
1 - A negative result in patients with COVID-19 like illness does not rule out infection and may require additional testing
2 - Additional validation testing pending
21
Infectious Disease Clinical ApproachDr. Ram Ramani, Infectious Disease MD, Metro Infectious Disease Consultants
22
Simplified Representation of Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) Viral Lifecycle and Potential Drug Targets
https://jamanetwork.com/journals/jama/fullarticle/2764727?guestAccessKey=d26e67ea-de1c-43de-91cf-
fd5afe0ef099&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=041320
23
Summary of Pharmacology for Select Proposed COVID-19 Treatments
https://jamanetwork.com/journals/jama/fullarticle/2764727?guestAccessKey=d26e67ea-de1c-43de-91cf-
fd5afe0ef099&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=041320
24
Summary of Pharmacology for Select Proposed COVID-19 Treatments
Continued
https://jamanetwork.com/journals/jama/fullarticle/2764727?guestAccessKey=d26e67ea-de1c-43de-91cf-
fd5afe0ef099&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=041320
25
CardiologyDr. Daniel Sauri, Director of Noninvasive Cardiology and Cardiac Imaging, AMITA
Heart and Vascular Medical Group, Cardiovascular Associates
26
Guidance for Patients Taking ACE/ARBs
• CONCERN: Angiotensin converting enzyme 2 (ACE2) receptors have been shown to be the
entry point into human cells for SARS-CoV-2, and ACEs/ ARBs have been shown to
upregulate ACE2 expression in the heart and even perhaps alveolar cells in the lung. This
prompted the question of whether ACEs/ARBs should be discontinued for patients at
high risk of COVID-19.
• EVIDENCE: Currently there are no experimental or clinical data demonstrating
beneficial or adverse outcomes with background use of ACE inhibitors, ARBs or
other RAAS antagonists in COVID-19 or among COVID-19 patients with a history of
cardiovascular disease.
• The HFSA, ACC, and AHA recommend continuation of RAAS antagonists for those
patients who currently take them for heart failure, hypertension, or ischemic heart disease.
• In the event patients with cardiovascular disease are diagnosed with COVID-19,
individualized treatment decisions should be made according to each patient's
hemodynamic status.
Sources:
https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19
https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2020/04/07/12/25/coronavirus-disease-2019-infection-and-ras
27
ECG Monitoring with Hydroxychloroquine
• CONCERN: Hydroxychloroquine (HCQ) is being utilized a treatment for COVID-19, but can
put patients at risk for prolonged QT and torsade de pointes.
• EVIDENCE: Chloroquine and HCQ were developed as anti-malarial drugs and are utilized
experimentally for COVID-19 because they inhibit pH-dependent effects of viral replication.
• When used with any other known QTc prolonging agents (lopinavir/ritonavir, amiodarone,
sotalol, haloperidol, ondansetron) these agents can have additive QTc-prolonging effects
and therefore, increased associated risk of arrhythmic death.
• If differential diagnosis includes bacterial pneumonia, avoid antibiotics that also prolong
QTc interval (e.g. levofloxacin, azithromycin, etc.). If atypical coverage is needed, use
doxycycline as an alternative.
• Seriously ill patients often have comorbidities that can increase risk of arrhythmias
including: hypokalemia, hypomagnesemia, fever and an inflammatory state.
Reference: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047521
28
Tisdale Risk Score for Drug Associated QTc Prolongation
29
Prior to Prescribing QTc Prolonging Medications
30
ECG Monitoring with Hydroxychloroquine
• Inpatient Monitoring Recommendations:
• To minimize healthcare associate exposure and PPE usage:• EKGs can be done by either the ECG technician (if available) or the bedside nurse during the
normal course of patient care.
• ECGs may be performed to coincide with "clustered" care between 2 and 4 hours after dosing.
• To further reduce exposure or save PPE resources, QTc monitoring may be performed
using surrogates for 12-lead ECG assessment, including:
• QTc monitoring via inpatient telemetry
• Standard protocol will be followed to decontaminate EKG equipment following their use
in COVID+ patients (i.e., same protocol used in patients positive for MRSA or C.
difficile).
• Consider initiation of hydroxychloroquine and then checking ECG on day 3 of
therapy. QTc by telemetry can be followed otherwise.
31
COVID-19 and Anticoagulation
• There is clear evidence that COVID-19 increases the risk of both venous and arterial
clotting with microvascular organ thrombosis and PE perhaps playing a role in
worse outcome.
• D-dimer appears to be the best single predictor of patients who will develop venous
thromboembolic disease.
• D-dimer >1,500 ng/ml had an 85% sensitivity and 89% specificity for predicting which
patients would develop DVT. This supports the concept of empiric anticoagulation for
patients with markedly elevated D-dimers (especially in situations where frequent CT
angiography is impossible due to logistic restraints).
• Until additional data is available, when to initiate full anticoagulation will remain
controversial. Among patients without risk factors for hemorrhage, empiric
anticoagulation may be reasonable for patients with elevated D-dimer levels.
Reference: https://emcrit.org/pulmcrit/dimer-cutoff-covid/
32
Anticoagulation and COVID-19: AMITA Joint PolicyAll COVID-19 patients should receive VTE prophylaxis with enoxaparin unless contraindicated. If D-dimer
>3mcg/mL and critically ill, increase to intermediate-dose weight-based VTE prophylaxis. If confirmed VTE,
begin therapeutic enoxaparin unless contraindicated.
Document can be found under Pulmonary & Critical Care Resources section at AMITAhealth.org/covid-19-AMITA
33
JAMA Clinical Guidelines for Volume Status Management in
COVID-19 Patients
• For acute resuscitation of adults with shock, the following are suggested:
• measuring dynamic parameters to assess fluid responsiveness
• using a conservative fluid administration strategy
• using crystalloids over colloids
• For adults with shock, the following are suggested:
• using norepinephrine as the first-line vasoactive
• use of either vasopressin or epinephrine as the first line if norepinephrine is not available
• dopamine is not recommended if norepinephrine is not available
• Adding vasopressin as a second-line agent is suggested if the target (60-65 mm
Hg) mean arterial pressure cannot be achieved by norepinephrine alone
Poston, J.T., Patel, B.K., Davis, A.M. (2020). Management of Critically Ill Adults with COVID-19. JAMA
Guidelines. https://jamanetwork.com/journals/jama/fullarticle/2763879
34
Caution with Interpretation of Troponin and BNP in COVID-19
Patients
• Brain Natriuretic Peptide (BNP) is an indicator of myocardial stress and frequently
elevated in patients diagnosed with COVID-19 and other severe respiratory illnesses at a
later course in the disease irrespective of volume status.
• HOWEVER, elevated BNP is negative prognostic indicators for patients with ARDS and
critical COVID-19 illness
• Clinical use: Can follow BNP to assess worse prognosis but also to clinically consider more
aggressive diuresis.
Reference: https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-
covid19, https://www.medscape.com/viewarticle/927205
35
Caution with Interpretation of Troponin and BNP in COVID-19
Patients
• Multiple studies have noted that Troponin are often elevated in critically ill COVID-19
patients. Worse prognostic outcomes.
• Given presence of abundant distribution of ACE2 – the binding site for the SARS-CoV-2 – in
cardiomyocytes, some have postulated that myocarditis and subsequent LV failure might
explain rise of troponin
• Causes for elevated Troponin can include:
• Ischemic ST changes who needs revascularization Type 1 MI plaque rupture
• Lower level troponin elevation in setting of supply demand mismatch Type 2 MI
• Higher degrees of troponin elevation associated with hyperinflammation and direct
myocardial injury (Myocarditis -trials for anakinra (IL-1 inhibitor) and colchicine
underway)
• Clinical use: Troponin elevation is consistent with worsening prognosis and
consideration for alternative therapies. If develops late in course could be
demand ischemia but be suspicious of myocarditis which usually presents late in
course and often as people are getting better.
https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext
36
Echo Safety Guidelines for COVID-19 Patients
• Echocardiography may be necessary to assess EF and fluid volume status in acutely ill
COVID-19 patients
• TTE or handheld echocardiography is preferred as it minimizes risks to providers (TEE is a
high risk procedure)
• AMITA procured numerous Phillips Lumify Handheld echo units for use by cardiology,
emergency medicine and critical care staff
• Guidelines for use can be located at: https://www.youtube.com/watch?v=mNVpGvUD6iQ
37
TEE Safety Guidelines for COVID-19 Patients
1. TEE is considered a high-risk procedure given the exposure to aerosolized respiratory products of the patients. As such, while COVID-19 cases are endemic to the area, a TEE should not be performed unless the result would yield an immediate change in patient management.
2. TEE should be urgent or emergent to require being done irrespective of COVID status at this point given high risk nature of TEE and asymptomatic transmission with COVID.
3. Decision to do a TEE should be multidisciplinary if necessary and assure absolute necessity at this time. The non invasive lab director can help adjudicate if there is disagreement about the necessity of the case.
4. If TEE is determined to be necessary, all providers in the room should have appropriate PPE including N95, impervious gown and face shield irrespective of COVID status.
5. If a short delay to determine COVID status can be determined by testing and will change management then testing should be considered.
6. All exams should have a patient with anesthesia facemask and port for placement of the TEE probe to reduce aerosolized respiratory products irrespective of COVID status
7. Consider alternatives to TEE imaging for certain questions. For example, CTA to rule out LAA thrombus rather then TEE. MRI use to rule out cardioembolic source. PET scan if available for evaluation of endocarditis. Of course if clinical question can be sufficiently answered by TTE that would be optimal.
8. Anesthesia can consider keeping the patient deep and proceduralist can use minimal ultrasound gel to avoid cough.
9. If a confirmed COVID-19 patient or PUI requires an emergent TEE for management, in consultation with anesthesia or intensivist staff, consider elective endotracheal intubation prior to performing TEE for airway isolation.
38
Medications and TreatmentSun Lee-Such, Vice President Pharmacy Services
39
COVID-19 Treatment – What do we know?
• No evidence from large randomized clinical trials that any potential
therapy improves outcomes in patients with either suspected or
confirmed COVID-19
• Mix of small trial results available – some showing efficacy, others
showing no difference vs. standard supportive care
• No clinical trial data supporting any prophylactic therapy
• More than 300 active clinical treatment trials underway with 109 including
pharmacologic therapy
• Chloroquine (CQ) and hydroxychloroquine (HCQ) reported as effective
from early reported experience and small studies in China and France
• CQ and HCQ became drugs of choice for large-scale due to its
availability and relatively low cost
Sanders JM, et al. Pharmacologic treatments for Coronavirus disease 2019 (COVID-19) –
A review. JAMA (2020), Published online April 13, 2020. doi:10.1001/jama.2020.6019
40
HCQ & Azithromycin in COVID-19 Treatment – Timeline
Data showing
Efficacy of
Hydroxychloroquine
with/without
Azithromycin
•Results from China
showed that HCQ can
efficiently inhibit
SARS-CoV-2 in vitro
•French non-
randomized study:
improved virologic
clearance (Subset of
6 w/ Azithromycin
show beneficial
results but baseline
viral load less)
Data showing
Lack of Efficacy of
Hydroxychloroquine
with/without
Azithromycin
US Government
Endorsement of
Hydroxychloroquine
for COVID-19
Treatment
CloroCovid-19
Clinical Trial
Halted due to
Toxicity and QTc
Prolongation
Recommendations
Emphasized in
AMITA COVID-19
Treatment and
QTc Monitoring
Guidance
Feb-
March
2020
April 13,
2020
March
2020
Mid-late
March
2020
March 29-
April 10,
2020
April 11,
2020
ACC/AHA
Releases
Guidance and
Warnings on
QTc Risks
•Shanghai study: No difference in clinical outcome
•French study on same HCQ + azithromycin regimen shows no benefit: 8/10 still COVID-positive on PCR – 1 patient died, 2 required transfer to ICU, 1 pt treatment discontinued due to QT prolongation
•3/19: President publicly endorses HCQ as “approved” therapy –within 24 hours, HCQ is on national shortage
•3/29: FDA issues emergency use authorization to treat hospitalized COVID-19 patients >50 kg
•3/30: AMITA Critical Drug Task Force formed
•3/29-4/10: ACC releases
Ventricular Arrhythmia Risk
Warning & ACC-AHA Joint
Statement on Drug
Interactions for QTc
•3/28: AMITA CV
published QTc
Monitoring guidance
•4/1: AMITA COVID-19 Tx
Guidelines Updated –
recommended
HCQ monotherapy &
defined HCQ use criteria
for COVID-19 positive
patients
•4/11: Brazilian high vs. low dose HCQ study (planned for 440 pts) halted due to higher mortality and QTc prolongation after 81 pts - all on ceftriaxone and azithromycin – no difference in efficacy
•4/13: AMITA COVID-19 Treatment Guidelines updatedto AVOID HCQ-Azithromycin combination therapy
•4/16: HCQ-Azithromycin
combination use
decreased by 95%
41
AMITA COVID-19 Treatment Triage Algorithm
Confirmed COVID-19 Positive
Admitted to Medical Floor
Admitted to ICU and
COVID-19 Positive or
Strong Clinical Suspicion
with Progressive Disease
Heart, lung, liver or renal disease, DM, on immune
modulators or immunosuppressants (e.g. equivalent to
prednisone ≥ 20mg/day), HIV, malignancy or asplenia
AND
At least ONE of the below are present:
SpO2 <90% on RA or PaO2 <70 mmHg or Alveolar-
arterial O2 gradient ≥ 35 mmHg
OR
HR >125 beats/min or respiratory rate >24
breaths/min
OR
SOFA ≥ 4, D-dimer ≥ 1 mg/L, or Lymphopenia
Consider treatment
with
Hydroxychloroquine*
Meets
Criteria
Does NOT
Meet Criteria
Supportive Care,
Close Monitoring
* Key Considerations with Hydroxychloroquine Use
• Hydroxychloroquine can cause QT-prolongation. Baseline EKG is
recommended. Review medication profile for other QT-prolonging
agents (e.g. azithromycin, levofloxacin, sotalol, amiodarone, etc.).
• When used with other known QTc prolonging agents, these agents
can have additive QTc-prolonging effects and therefore, increased
associated risk of arrhythmic death. Refer to COVID-19 Cardiac
Monitoring and QTc Assessment Guidelines.
• If differential diagnosis includes bacterial pneumonia, avoid antibiotics
that also prolong QTc interval (e.g. levofloxacin, azithromycin, etc.).
If atypical coverage is needed, use doxycycline as an alternative.
42
Cardiac Toxicity and QT Prolongation
COVID-19 Treatments:
Hydroxychloroquine,
Azithromycin,
Lopinavir/Ritonavir
Antibiotics with
QT-prolonging potential
(e.g. Azithromycin,
levofloxacin, etc.)
Other QT-prolonging medications*
(e.g. Amiodarone, sotalol, haloperidol,
quetiapine, etc.)
Increased
potential
for QT
prolongation
Increased risk
for drug-induced
arrhythmias
Increased risk
for drug-induced
torsades de
pointes
Increased risk of
drug-induced
cardiac death
Other factors with increased risk of
torsades de pointes
(Structural heart disease, congenital long-
QT syndromes, electrolyte disturbances,
hepatic/renal failure, female sex)
+/–
+/–
+/–
*Complete list of QT prolonging agents available at: https://www.crediblemeds.org/
• Discontinue and avoid all other non-critical QT-prolonging agents
• Assess baseline ECG, renal function, hepatic function, serum potassium
and magnesium levels
• Consult Cardiology and monitor QTc interval periodically based on
baseline measurement
43
HCQ and Azithromycin Use for COVID-19 – Key Points
1. Due to the risk of potential significant cardiac toxicity, including sudden
death and lack of evidence displaying clinical benefit, the addition of
azithromycin to hydroxychloroquine for the management of COVID-19
should be avoided.
2. Criteria have been added for when HCQ should be considered and avoided
in patients with suspected or confirmed COVID-19 in AMITA COVID-19
Treatment Guideline.
3. The decision to start HCQ should be based on shared clinical decision-
making, in which the patient is informed about possible benefits—such as
low-quality evidence—and potential side effects, particularly QTc prolonging
effects. In addition, the patient's condition should be sufficiently severe to
warrant this investigational therapy. Please click here for more information.
4. If differential diagnosis includes bacterial pneumonia, avoid antibiotics that
also prolong QTc interval, such as levofloxacin, azithromycin, etc. If atypical
coverage is needed, use doxycycline as an alternative.
44
Respiratory ClinicsDr. Reinhold Llerena, President, AMITA Medical Group
45
AMITA Health Respiratory Centers
Mount Prospect1754 W. Golf Rd.
Mt. Prospect, IL 60056
Phone: 224.265.9000 or
224.265.9010;
press 2 (for Immediate Care)
Fax: 224.265.9041
Lincolnwood7380 N. Lincoln
Lincolnwood, IL 60712
Phone: 847.568.7400
Fax: 847.568.7440
*Adults only location
Chicago / Archer6084 S. Archer Ave., Floor 1
Chicago, IL 60638
Phone: 224.273.6000
Fax: 224.273.6099
The new AMITA Health Respiratory Centers will offer a comprehensive assessment in a safe, controlled
environment for patients with acute respiratory symptoms having an impact on chronic conditions such as
COPD, Asthma, DM, cardiac conditions or acute newly developed symptoms related to COVID-19-like illness.
1
2
3
1
2
3
Note: AHMG PCPs should schedule internally through their Epic or Athena EMRs
46
Seeking Care at AMITA Health Respiratory Centers
Symptoms Addressed• Flu symptoms
• Sore throat
• Fever
• Cold symptoms
• Diarrhea
• Acute asthma: wheezing or chest tightening
• COPD exacerbation: shortness of breath
• Congestive Heart Failure
• Respiratory infections
Referring a Patient to the Respiratory Center
1. Ordering physician to fax (required) referral
2. Respiratory Center to contact patient to schedule
appointment
3. Patient to bring ID, insurance card and all respiratory
medication, including inhalers to visit
The new AMITA Health Respiratory Centers will have the ability to provide interim care including oxygen,
respiratory treatments and physical assessment, with the intent to transition patients back to their regular
primary care provider.
Documents under Testing Guidance section at AMITAhealth.org/covid-19-AMITA
47
Insurances Accepted at AMITA Health Respiratory Centers
• Ascension Complete MA
• BCBS Medicare Advantage HMO Sites 741, 760, 761, 762, 763, 764, 765
• BCBS MA PPO
• BCBS PPO ACO
• Bright Health MA HMO
• Clear Spring MA HMO
• Clear Spring Health
• Cigna Health Spring MA HMO, MA PPO
• Humana MA HMO/PPO/PFFS
• Medicare FFS
Medicare
Commercial
• ACTIN PPO
• BCBS HMO-197, 488, 494, 495, 496, 497, 498, 499, 500
• HMOI Blue Advantage HMO
• Blue Precision
• Humana HMO
• Cigna One Health
• Cigna PPO/POS/CAC
• Cigna Local Plus
• Cigna Connect IFP HMO
• HFN PPO
• HealthLInk PPO/Unicare
• Humana PPO/POS/ChoiceCare
• MultiPlan/Beech Street PPO
• PHCS PPO
• SmartHealth PPO
• Unite Here Health
Documents under Testing Guidance section at AMITAhealth.org/covid-19-AMITA
48
Closing RemarksDr. Joseph Lagattuta, CIN Board Chair
49
Redeploying Available Clinicians
Contact Amy Kinnett-Calhoun
Clinicians (MD, DO, APN, PA, RN, MA, etc.) with extra capacity to volunteer clinical skills or provide support,
particularly (but not limited to) those with expertise in pulmonary, critical care or emergency medicine may be
in need across the AMITA Health system.
Family / Internal Medicine Physicians OR
Inpatient Hospitalists
Complete one of the following to volunteer:
1. Complete form: Click Here for Form
2. Call: AMITA Physician Hotline at 224.273.3900 weekdays 8am-5pm
3. Email: [email protected]
Physician Specialists OR
Other Clinical Staff
50
Thank you!
Updated Hours:
AMITA Physician Hotline Phone Number
224.273.3900 from 8am to 5pm weekdays for the foreseeable future
AMITA Physician Hotline Email